The 3CLglow Assay is a SARS-CoV-2 3CLpro inhibitor assay, a new technology developed by Montana Molecular in response to the COVID-19 pandemic. This assay provides a robust, biologically meaningful tool to evaluate therapeutic drugs that target SARS-CoV-2 replication.
- 3C-like protease (3CLpro, Mpro, or Main protease) is essential for SARS-CoV-2 replication.
- Discover new 3CL protease inhibitors.
- A single BacMam delivers a gene encoding the green fluorescent 3CLglow Sensor as well as constitutively expressed red protein to check cell health.
- BSL-1 kit is safe and easy to use.
Simple Assay Steps
- Day 1 – Plate 35,000 HEK293 cells in each well.
- Day 2 – Make transduction mix by combining 3CLglow BacMam, 3CLpro Enzyme, complete media, and sodium butyrate (included in 3CLglow Assay Kit).
- Day 3 – Add inhibitor compounds and measure green and red fluorescence in either an endpoint assay to maximize throughput, or a kinetic assay for real-time detection of inhibitor action in living cells.
Images captured with a BioTek LionHeart FX automated microscope
3CLglow – Measure 3CLpro Inhibition
- GC376 inhibits 3CLpro enzyme and is a reliable control for 3CLglow assay.
- EC50 value for GC376 is consistent with reports by Vuong et.al. 2020 using live SARS-CoV-2 in culture.
- Compatible with detection on fluorescence plate readers or imaging systems.
GC376 inhibits 3CLpro and is a reliable control for 3CLglow assays.
HEK 293 cells expressing both SARS-CoV-2 3CLprotease and fluorescent biosensor. Images captured on the BioTek LionHeart imaging plate reader.
